INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
WEIGHT-LOSS DRUG TRACKER

Retatrutide

Retatrutide is an investigational triple-receptor agonist. Phase 3 evidence is available, while regulatory approval remains a separate milestone.

Single conceptual retatrutide carton labeled Illustration and Investigational.
Conceptual RETATRUTIDE carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.

Retatrutide is an investigational triple-receptor agonist. Phase 3 evidence is available, while regulatory approval remains a separate milestone.

TRIUMPH-1 evaluated adults with obesity without diabetes over 80 weeks. The published treatment-regimen estimate differs in purpose from hypothetical continued-treatment estimates. Read the paper’s population, analysis, and adverse-event reporting beside any weight-loss percentage.

The trial registry identifies the study design and sponsor. It does not verify clinical-trial eligibility for a reader or authenticate products sold outside the research setting.

There is no approved dose or brand verified here. An online product using the molecule’s name should not be assumed equivalent to the clinical-trial material.

Regulatory status checked on 3 October 2026

United States: FDA states retatrutide is not a component of an FDA-approved drug; current sponsor sources call it investigational. Trial publication does not establish routine marketing approval.

European Union: EU marketing authorisation has not been verified in this review. A research or pediatric-development document is not sufficient evidence of authorisation.

Official records and primary evidence

Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.

Official references

  1. FDA GLP-1 safety communication ↗
  2. Retatrutide development update ↗
  3. TRIUMPH-1 Phase 3 paper ↗
  4. TRIUMPH-1 trial registry ↗

Clinical trial evidence

Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.

TRIUMPH-1

NCT05929066 · Retatrutide profile

Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
completed
Registry enrollment
2335 (actual)
Published analysis population
2339
Analysis time point
80 weeks
Population
Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
Registry checked
2026-10-03

Registry actual enrollment 2335 differs from 2339 randomized in the paper; the reason was not established from these sources.

Published mean body-weight change at 80 weeks · treatment-regimen (intention-to-treat)
Historical trial armMean change from baseline
retatrutide 4 mg trial arm-17.6%
retatrutide 9 mg trial arm-23.7%
retatrutide 12 mg trial arm-25.0%
placebo-3.9%

Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.

Original study abstract · Full registry record

The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.

Evidence, explainers and reporting

The medicine profile is a reference point. These articles address narrower questions and developments.

← Back to the drug tracker
Cookie policy